Use of lupin conglutin for the treatment of type II diabetes

Details Use of lupin conglutin for the treatment of type II diabetes Use of lupin conglutin for the treatment of type II diabetes

2008-01-29

2008-01-29

Mondesi, Robert (Department: 1652)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

07323441

ABSTRACT:
A method for the use of lupin conglutin gamma or of proteins showing homology higher than 50% with lupin conglutin gamma, for the preparation of a medicament, food supplements or foods for the treatment of type II diabetes, pharmaceutical and nutritional compositions containing lupin conglutin gamma, and the use of lupin conglutin gamma as therapeutical agent, in particular as hypoglycemizing agent. Lupin conglutin gamma may be used in pure form or in form of extracts, mixtures or concentrates.

REFERENCES:
AAC49787, 131 aa, linear PLN Sep. 26, 2002, conglutin alpha [Lupinus angustifolius], pp. 1-2.
AAB31199 ,31 aa, linear PLN Nov. 8, 1994 conglutin gamma heavy subunit, LalbC gamma heavy subunit, p. 1.
Q96474, 81 aa, linear PLN Feb. 7, 2006, Albumin 1 precursor (A1) Contains: Albumin 1 chain b (A1b), pp. 1-2.
Duranti et al., Thermal stabilities of lupin seed conglutin gamma protomers and tetramers, J Agric Food Chem. Apr. 2000, vol. 48, No. 4, pp. 1118-11123.
Scarafoni A. et al., Cloning, sequencing and expression in the seeds and radicles of two Lupinus albus conglutin gamma genes, Biochim Biophys Acta. May 2001, pp. vol. 1519, No. 1-2 pp. 147-151.
Pereira, Frederico C. et al: “Insulinotropic action of white lupine seeds (Lupinus albus L.): effects on ion fluxes and insulin secretion from isolated pancreatic islets” Biomedical Research, 22(2), 103-109 Coden: Bresd5; ISSN: 0388-6107, 2001, XP009033243 *p. 104, Preparation of lupine extracts* P. 108, col. 1, para 2-p.108, col. 2, para* abstract.
Woldemichael G M et al.: “Tripertene glycosides ofLupinus angustifolius” Phytochemistry, Pergamon Press, GB, vol. 60, No. 4, Jun. 2002, pp. 323-327, XP004354728 ISSN: 0031-9422 *p. 323, Introduction *.
Database Chemabs ′Online! Chemical Abstracts Service, Columbus, Ohio, US; Villarroel, Mario et al: “Chemical, sensory and clinical characterization of lupine marmalades” XP002287708 retrieved from STN Database accession No. 127: 345533 cited in the application abstract.
Waesche A et al: “New processing of lupin protein isolates and functional properties.” Nahrung 45 (6) 393-395 2001Cess Eng., Fraunhofer-Inst. for Process Eng. & Packaging, Giggenhauserstr. 35, D-85354 Freising, Germany. E-Mail Wae(A)Ivv.Fhg.De, 2001, XP009033277 *p. 393, Materials and methods* abstract.
Sirtori C R et al: “Proteins of White Lupin Seed, a Naturally Isoflavone-Poor Legume, Reduce Cholesterolemia in Rats and Increase LDL Receptor Activity in HepG2 Cells” Journal of Nutrition 2004 United States , vol. 134, No. 1, 2004, pp. 18-23, XP001182166 ISSN: 0022-3166 table 4 & Archivos Latinoamericanos de Nutricion, 46 (3), 234-237 Coden: Alanbh; ISSN: 0004-0622, 1996.
Komatsu S et al: “Plant basic 7 S globulin-like proteins have insulin and insulin-like growth factor binding activity.” Febs Letters, Dec. 9, 1991, vol. 294, No. 3, Dec. 9, 1991, pp. 210-212, XP002287707 ISSN: 0014-5793 * p. 210, Introduction, last paragraph * * Fig. 1 *.

Affiliated with

Also associated with

Rating

Use of lupin conglutin for the treatment of type II diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of lupin conglutin for the treatment of type II diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of lupin conglutin for the treatment of type II diabetes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2805793